Paradigm Medical Announces Plans to Release Its New Corneal Topographer, the Paravue, in the United States Market
2009年6月1日 - 9:30PM
Marketwired
Paradigm Medical Industries, Inc. (OTCBB: PDMI) announced today
that the Company will soon begin to introduce the first of its four
new ophthalmic diagnostic devices, the Paravue, during the
remainder of 2009. The Paravue is a sophisticated topographer
utilizing Placido Disk Technology and an advanced software to
provide accurate and detailed analysis of the anterior corneal
surface.
Corneal topography -- also known as videokeratography or corneal
mapping -- represents a significant advance in the measurement of
the corneal curvature. Most corneal topographers evaluate 8,000 to
10,000 specific points across the entire corneal surface. By
contrast, the Paravue processes more than 100,000 points. It also
offers corneal wave front analysis with 2, 3 or 4 maps available
for comparison.
The Paravue provides both a qualitative and quantitative
evaluation of corneal curvature. It does so by utilizing a big
placido disk with 24 concentric rings, which project onto the
cornea to create a virtual image. The device compares this image to
the target size, and the computer then calculates the corneal
curvature. Advanced features including advanced rings editing,
variable scales, refractive power map and more make the Paravue a
valuable tool in the optometric and ophthalmic clinics.
"The addition of the Paravue to our existing ophthalmic product
line fills an important segment that was missing," said Paradigm
Medical President, Stephen Davis. "We are excited to offer not just
another topographer, but one with many impressive features and
incredibly friendly software that provides ease of use, flexible
mapping and accuracy."
About Paradigm Medical Industries, Inc.
Headquartered in Salt Lake City, UT, Paradigm Medical
Industries, Inc. is a medical device company that develops,
manufactures and distributes cutting edge, new innovative products
in the diagnostic ultrasound and early glaucoma detection markets.
Paradigm has the only patented technology utilizing photon laser
for cataract removal. The Company is poised to capture a niche
market within the Glaucoma and ultrasound microscopy fields.
Paradigm Medical Industries markets its products to
ophthalmologists, optometrists, universities, and clinics
throughout the United States, as well as internationally.
For more information, please visit: www.paradigm-medical.com
This press release contains statements that, if not verifiable
historic fact, may be viewed as forward-looking statements that
could predict future events and outcomes with respect to Paradigm
and its business. The predictions embodied in these statements will
involve risk and uncertainties and, accordingly, actual results may
differ significantly from the results discussed or implied in such
forward-looking statements.
Contact: Paradigm Medical Industries, Inc. Stephen Davis
President 801-977-8970 www.paradigm-medical.com
Paradigm Medical Industr... (CE) (USOTC:PDMI)
過去 株価チャート
から 11 2024 まで 12 2024
Paradigm Medical Industr... (CE) (USOTC:PDMI)
過去 株価チャート
から 12 2023 まで 12 2024